INTRODUCTION
Hepatitis C (HC) is an infectious disease caused by the hepatitis C virus (HCV). It is considered a public health problem by the World Health Organization (WHO) because it affects 2% to 3% of the world's population and is associated with high morbidity and mortality rates. Seventy to ninety percent of infected patients progress to chronic liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) and these diseases are sometimes associated with liver transplantation. (1, 2) HC affects vulnerable and largely unattended populations such as users of injected drugs and people with inadequate healthcare.
Chronic HC is also associated with extrahepatic manifestations including dermatological, rheumatologic, hematological and renal disorders. ( 3) The latter may manifest with proteinuria, a decreased glomerular filtration rate (GFR), or even chronic kidney disease (CKD). (3) (4) (5) (6) (7) (8) The development of CKD due to HCV may be related to the development of glomerulonephritis mediated by the accumulation of cryoglobulins, immune complexes of antibodies against HCV, or by deposition of amyloid. (3, 5, 9, 10) Patients on hemodialysis (HD) are at greater risk of acquiring HCV infections due to repeated exposure to bloodborne pathogens, the need for transfusions, the duration of dialysis, the need for intravenous access and the manipulation of the catheter. (11, 12) The result is high prevalence of HCV infection in patients with terminal CKD. (12) (13) (14) (15) (16) (17) This prevalence is 53% in Colombia. (18) Worldwide, the prevalence of HC is higher in patients over 50 years of age, (19) and, the highest proportion of cases reported in Colombia is found among patients with 65 years old and over. (20) This population is more prone to hypertension, dyslipidemia, diabetes mellitus, cardiovascular disease and obesity which constitute additional risk factors for the development of CKD. (5, 21, 22) Similarly, typical physiological alterations of age, especially of those organs responsible for metabolism and drug excretion, (23) provoke pharmacological variability which makes this population even more vulnerable to adverse drug events (ADE). (24) Consequently, elderly patients with CKD and chronic HC constitute a population with great pharmacotherapeutic complexity. Furthermore, treatment options for HC in patients with stage 4 or 5 CKD are limited due to poor tolerance and low effectiveness of conventional therapies with interferon (IFN) and ribavirin (RBV). (13, 17, 25) . In addition, there is limited information on the safety and efficacy of current direct-acting antiviral (ADA) regimens given that they have not been adequately evaluated in patients with CKD during clinical trials. (12, 26) For these reasons, information on the dosage, effectiveness and safety of antivirals for treating HC in elderly patients with CKD is needed in order to achieve the best possible health outcomes and avoid ADE. Consequently, the objective of this review was to systematize the medication dosage information for chronic HC from studies or reports that included elderly patients with CKD.
MATERIALS AND METHODS
We searched PubMed/Medline for the following terms: "Hepatitis C" [Mesh] AND "Aged" [Mesh] AND "Renal Insufficiency" [Mesh] filtered for studies conducted in humans published between August 1, 2012 and August 1, 2017 in English or Spanish with access to full text. Studies and report whose samples included elderly patients with CKD and HC were included. Articles were excluded if they did not mention pharmacological management of HC in patients with CKD, articles with incomplete dosage information and articles related to drugs withdrawn by the Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the National Institute of Drug and Food Surveillance of Colombia (INVIMA -Instituto Nacional de Vigilancia de Medicamentos y Alimentos). The search was complemented with publications considered relevant that were referenced in the articles found.
The titles and abstracts of all the articles identified were reviewed by both authors, and decisions to include or exclude articles were made by consensus.
The following information was structured in a database: medication evaluated, HCV genotype, GFR of the patient (s) studied, stage of CKD, dosage used, information on elimination of dialysis, efficacy/effectiveness, ADE, type of study and reference. Efficacy/effectiveness was reported as sustained viral response and defined as undetectable viral load at 12 or 24 weeks after the end of treatment (sustained virological response, SVR12 or SVR24).
The results obtained were compared with dosages for patients with normal renal functioning (Table 1) and with dosage adjustment recommendations presented in UpToDate® and Micromedex®, two databases frequently used by physicians and pharmacists for posology.
RESULTS
We identified 83 articles of which 14 were included. In addition, four articles referenced in the reviewed publications were considered relevant (Figure 1) .
Observational analytical studies accounted for 38.9% of the articles, descriptive observational studies accounted for 33.3% and experimental studies accounted for 27.8%.
Information was identified for seven therapeutic strategies using second generation direct-acting antivirals (DAAs) including elbasvir/grazoprevir, paritaprevir/ ombitasvir/ritonavir, dasabuvir, sofosbuvir, simeprevir, daclatasvir and asunaprevir combined with PEG-IFN and/ or RBV. The studies and reports reviewed contained information on the use of anti-HCV medications for patients between 18 and 79 years of age. Table 2 shows a summary of the dosage recommendations according to renal function from UpToDate® and Micromedex®) and from the articles and information reviewed for this article. (27, 33, 36) . No information available regarding elimination by HD. They can be administered at any time -before or after -HD. (27) PD: 150 mg every 24 hours (No dose adjustment necessary) (36) . No information available regarding elimination by PD.
Medication

GNT GFR Recommendations
Uptodate ( Authors such as Bunchorntavakul C et al. (12) have evaluated the treatment of HCV in patients with GFRs <30 mL/min/1.73 m2 who underwent kidney transplantation or who had CKD related to HCV. Based on the information found, they developed strategies for the management of HCV in patients with CKD and TR that use PEG-IFN, RBV, sofosbuvir, simeprevir, boceprevir and telaprevir (The last two have been withdrawn from the market). Similarly, Sorbera et al. produced a table with dosage recommendations for sofosbuvir, simeprevir, ledipasvir, daclatasvir, ombitasvir/paritaprevir and dasabuvir for use in patients with renal impairment. (11) Unlike the other reviews discussed, this paper presents recommendations about seven therapeutic strategies that use PEG-IFN and RBV and second generation direct acting antivirals: elbasvir/grazoprevir, paritaprevir/ombitasvir/ritonavir, dasabuvir, sofosbuvir, simeprevir, daclatasvir and asunaprevir. We expand the information about the use of sofosbuvir in elderly patients whose GFR is less than 30 mL/min and who are on dialysis. Bunchorntavakul et al. could not include doses for daclatasvir, ombitasvir/ paritaprevir, dasabuvir, or elbasvir/grazoprevir since they were not available at the time of their review, and Sorbera et al. neither provided data on the use of asunaprevir at any stage of CKD nor did they provide information on elbasvir/grazoprevir. (12, 11) In addition, those reviews did not report the ages of the patients included in the studies they reviewed, nor did they present information on ADEs which makes it impossible to know the use, dosage and safety of DAAs in elderly patients with CKD.
Treatment of HC in elderly patients with CKD
Preferably, elderly patients with HC and CKD should be treated with drugs that are not excreted by the kidneys to
DISCUSSION
For patients with chronic HC, antiviral treatment is considered essential for preventing complications and improving prognoses, especially when there is evidence of extrahepatic manifestations such as renal alterations that may require dialysis or kidney transplantation. (13, 25) In addition, failure to treat patients who have acquired HCV through dialysis and who are waiting for kidney transplantation can allow HC to progress to HCC adding a need for liver transplantation thus adversely affecting allocation of organs and resources for organ transplantation. (27) Failure to treat HCV infections in patients with CKD reduces patient and graft survival (in cases of transplant patients and transplant candidates) and increases mortality. (8, 12-14, 28, 29) This review has allowed us to expand the amount of dosing information available for antiviral drugs used to treat HCV in elderly patients with CKD. This information has been structured into a table which may be useful for health professionals involved in prescribing and monitoring these patients. We found information that was not available in UpToDate® and Micromedex®, frequently used databases. This information includes doses of paritaprevir/ ombitasvir/ritonavir and dasabuvir for patients with HD and peritoneal dialysis (PD) as well as dosage information for sofosbuvir and simeprevir treatment of patients with GFR less than 30 mL/min who are on either HD or PD. Similarly, the existing information on UpToDate® and Micromedex® has been confirmed for daclatasvir, elbasvir/ grazoprevir, PEG-IFN and RBV while information found in UpToDate® on the use of asunaprevir for patients on HD was found to be unsupported because it has not been approved in the United States. This information was not available in Micromedex®.
Among the dosing recommendations that varied the most were those in studies and reports about RBV. Three of the five studies that reported its use in patients with HD showed that doses administered differed from the 200 mg a day recommended in the information of the insert (30) Sofosbuvir is one of the most widely used drugs because it inhibits replication of multiple HCV genotypes, has a high genetic barrier to resistance, is well tolerated and has limited potential for drug-drug interactions. (46) Administration of the full dose (400 mg every 24 hours) in elderly patients with stage 4 and 5 CKD, including those on HD or PD can be considered when none of the schemes that are eliminated through the liver are available (elbasvir/ grazoprevir, paritaprevir/ombitasvir/ritonavir/dasabuvir, daclatasvir/asunaprevir) or when they are contraindicated. This is the case for patients with decompensated cirrhosis (Child-Pugh B or C) for whom the use of elbasvir /grazoprevir and paritaprevir/ombitasvir/ritonavir/dasabuvir are not indicated.
Given that, as of publication of this review, Colombian and international clinical practice guidelines have not recommended the use of schemes containing sofosbuvir for patients with stages 4 or 5 CKD, including end-stage renal disease, the recommendations of this review should be considered with caution. The decision to treat HC in elderly patients with CKD, especially stages 4 and 5, should be individualized, should consider available medications, should consider risks and expected benefits of treatment, and should consider the patient's life expectancy and comorbidities. When a decision has been made to use DAAs appropriate dosage adjustments, careful follow-up of renal function, and careful monitoring for the appearance of ADE and SVR are all necessary.
Similarly, the need for prospective safety and effectiveness studies of DAAs for treatment of HCV in elderly patients with CKD is highlighted.
LIMITATIONS
This review has several limitations, and the information in it should be interpreted with caution by prescribing physicians. On one hand, we only searched the PubMed/ Medline database while the general recommendation for this type of study is to search in two or more databases. However, the review of the references of the articles included could mitigate this limitation. On the other hand, the articles reviewed include information on patients of various age groups, but usually did not classify data according to age. Consequently, it was not possible to extract the dosing and efficacy information exclusively for patients 65 years or older. Despite this, the studies reviewed show the use of DAAs in this age group which could indicate the absence of problems with their use.
In addition, none of the articles reviewed included information for patients aged 80 and older. Consequently, it is prevent accumulation of the drugs or their metabolites. On the one hand, elbasvir/grazoprevir, paritaprevir/ombitasvir/ritonavir, dasabuvir, daclatasvir, asunaprevir, ledipasvir and simeprevir are metabolized mainly by the liver while sofosbuvir, the cornerstone of several schemes, has renal excretion (through the inactive metabolite GS-331007). (16, 26, 44) This may limit concomitant use of other DAAs such as ledipasvir, simeprevir and daclatasvir in patients with TCKD. (26) Currently, the sofosbuvir insert does not contain dosage recommendations for patients whose GFRs are less than 30 mL/min/1.73 m2 or who have TCKD because there is evidence of higher exposures (up to 20 times) of the predominant sofosbuvir metabolite, GS331007. (4, 5) However, studies included in this review have shown the successful use of full doses of sofosbuvir (400 mg every 24 hours) in stages 4 and 5 including treatment of patients on HD and PD without major implications for safety. Also, some of the ADEs reported in patients who used sofosbuvir could be primarily associated with concomitant use of PEG-IFN and/or RBV.
Patients with HD should be considered to eliminate a considerable amount sofosbuvir and its predominant metabolite, (45) but authors who reported the use of full doses of this drug in this population do not provide information on the most appropriate time to administer it. For example, Nazario et al. (27) administered sofosbuvir and simeprevir at any time, before or after dialysis, and achieved SVR 12 in 100% of the patients. ADE was not documented during treatment in 76% (13/17) of the patients. Reported ADEs were insomnia (12%), nausea (5%), headache (5%) and anemia (5%). (27) In terms of effectiveness, DAAs achieved SVR12 in 83.3% to 100% of the study populations with high cure rates in patients treated with these schemes. Bhamidimarri et al. (36) , achieved an SVR12 in 83.3% of their HD and PD patients (10/12) using adjusted dosages of sofosbuvir while they achieved SVR12 of 100% for patients with GFRs between 8 and15 mL/min (3/3).
Several of the ADEs reported in the studies of different drugs may be associated with high prevalences of comorbidities such as hypertension, diabetes mellitus and cardiovascular disease in elderly patients with CKD, especially in patients on dialysis.
This structured review offers systematized information on DAA guidelines used in elderly patients with HC and CKD especially in routine clinical practice as well as information on which schemes have proven to be effective and safe in treated patients. This information can strengthen the processes of prescription and pharmacotherapy follow-up thus contributing to the effectiveness and safety of treatment.
